P11: FDG-PET/CT for early prediction of response to first line platinum chemotherapy in advanced thymic epithelial tumors
Poster Session

P11: 18FDG-PET/CT for early prediction of response to first line platinum chemotherapy in advanced thymic epithelial tumors

Giovannella Palmieri1, Margaret Ottaviano1, Silvana Del Vecchio2, Sabrina Segreto2, Irene Tucci1, Vincenzo Damiano1

1Rare Tumors, Medical Oncology, Federico II University of Naples, Naples, Italy; 2Federico II University of Naples, Naples, Italy


Background: To investigate the value of the metabolic tumor response assessed with 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), compared with clinicobiological markers, to predict the response disease to first line platinum based chemotherapy in advanced thymic epithelial tumors (TETs).

Methods: Twenty patients with diagnosis of TET and stage of disease III and IV sec, Masaoka-Koga, were retrospectively included in this monocentric study. Different pre-treatment clinical, biological and pathological parameters, including histotype sec, WHO 2004 and stage of disease sec, Masaoka-Koga were assessed. Tumor glucose metabolism at baseline and its change after the first line platinum based chemotherapy (from 4 to 6 cycles) were assessed using FDG-PET, moreover the response disease was assessed using total body CT scan for the evaluation of RECIST criteria 1.1.

Results: Twelve patients had an objective response to the first line platinum based chemotherapy according RECIST criteria 1.1 and all of them started with a SUVmax at baseline major than 5, indeed the other eight patients, non-responders to chemotherapy, had a SUVmax at baseline minor than 5.

Conclusions: It is important to define the chemosensitivity of advanced TETs early. Combining bio-pathological parameters with the metabolism at baseline assessed with FDG-PET can help the physician to early predict the probability of obtaining a disease response to first line platinum based chemotherapy. The SUVmax cut off of 5 at 18FDG-PET/CT performed at baseline treatment might be a new parameter for choosing the most powerful first line of chemotherapy. Given these results, further prospective studies are needed to establish a new first line therapy in advanced TETs with a low SUVmax at baseline, non-responders to conventional chemotherapy.

Keywords: 18FDG-PET/CT; thymic epithelial tumors; response


doi: 10.3978/j.issn.2072-1439.2015.AB080


Cite this abstract as: Palmieri G, Ottaviano M, Del Vecchio S, Segreto S, Tucci I, Damiano V. P11: 18FDG-PET/CT for early prediction of response to first line platinum chemotherapy in advanced thymic epithelial tumors. J Thorac Dis 2015;7(Suppl 3):AB080. doi: 10.3978/j.issn.2072-1439.2015.AB080

Article Options

Download Citation